A meta-analysis of 10 RCTs shows medical cannabis can reduce dementia-related agitation—a behavioral symptom that devastates both patients and caregivers. Cannabinoids showed effectiveness comparable to antipsychotics but with a safer profile, especially at doses above 10 mg THC-equivalent. This evidence offers caregivers and physicians a potential alternative when antipsychotic medications carry too much risk